These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24697248)

  • 1. Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies.
    Salvo F; Antoniazzi S; Duong M; Molimard M; Bazin F; Fourrier-Réglat A; Pariente A; Moore N
    Expert Opin Drug Saf; 2014 May; 13(5):573-85. PubMed ID: 24697248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.
    Moore N
    Drug Saf; 2020 Apr; 43(4):301-318. PubMed ID: 31916080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity.
    Singh BK; Haque SE; Pillai KK
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):143-56. PubMed ID: 24215502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs.
    Salpeter SR; Gregor P; Ormiston TM; Whitlock R; Raina P; Thabane L; Topol EJ
    Am J Med; 2006 Jul; 119(7):552-9. PubMed ID: 16828623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectivity of NSAIDs for COX-2 and cardiovascular outcome.
    Maxwell SR; Payne RA; Murray GD; Webb DJ
    Br J Clin Pharmacol; 2006 Aug; 62(2):243-5. PubMed ID: 16842401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ; Benraad HB; Rasker JJ
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review.
    Asghar W; Jamali F
    Inflammopharmacology; 2015 Feb; 23(1):1-16. PubMed ID: 25515365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M; Chowienczyk P; Kirkham B
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
    Amer M; Bead VR; Bathon J; Blumenthal RS; Edwards DN
    Cardiol Rev; 2010; 18(4):204-12. PubMed ID: 20539104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.